

Dr Emmanuel Garcion (Research Director at Inserm, Group leader of GLIAD at the CRCINA, Inserm, Université d'Angers, France)

Dr Emmanuel Garcion obtained a PhD in Neurosciences at Pierre and Marie Curie University (Paris VI) in 1997 for his pioneering work demonstrating that the hormone, vitamin D, is an important modulator of inflammatory and immune responses in the central nervous system (CNS). During his postdoctoral training at the University of Cambridge (UK) until end of 2001, he established an essential role for the extracellular matrix through tenascin-C in the development of neural precursors. In 2002, he turned his attention to the possibility of delivering therapeutic molecules into the CNS. With an emphasis on neuro-oncology concepts, he studied the interest of implantable polymer systems. Following his recruitment at Inserm in Angers in 2005, he focused on more dynamic and versatile drug carriers such as nanomedicines. In 2017, his team was certified by Inserm within the CRCINA (Nantes-Angers Cancer and Immunology Research Center). By developing models of glioblastoma in animals, his work is to interpret the fundamental mechanisms underlying the development of glioblastoma and to develop relevant loco-regional treatment, among which micro-nanomedicine application, to achieve curative efficacy. Particular attention is paid to vectorized radiation therapy, the role of miRNAs and tumor cell trapping.